✦ LIBER ✦

High-dose cytosine arabinoside in previously treated patients with poor-prognosis non-Hodgkin's lymphoma

✍ Scribed by David J. Adelstein; Hillard M. Lazarus; John D. Hines; Roger H. Herzig

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 399 KB
Volume: 56
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19851001)56:7<1493::aid-cncr2820560702>3.0.co;2-m

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Non-melanoma skin cancer may be a marker

Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma

✍ Henrik Hjalgrim; Morten Frisch; Hans H. Storm; Bengt Glimelius; Jakob Bøje Peder 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 78 KB 👁 2 views

According to recent results, patients with non-melanoma skin cancers are at increased risk of developing non-Hodgkin's lymphoma (NHL). The prognostic significance of this association is unknown. Two cohorts of patients with a first diagnosis of non-melanoma skin cancer and a subsequent diagnosis of

Oncogenic aberrations in the p53 pathway

Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in b-cell non-Hodgkin's lymphoma

✍ Trond Stokke; Eivind Galteland; Harald Holte; Lars Smedshammer; Zhenhe Suo; Erle 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 225 KB 👁 2 views

Fractionated cyclophosphamide and back t

Fractionated cyclophosphamide and back to back high dose methotrexate and cytosine arabinoside improves outcome in patients with stage III high grade small non-cleaved cell lymphomas (Snccl): A randomized trial of the pediatric oncology group

✍ Brecher, Martin L.; Schwenn, Molly R.; Coppes, Max J.; Bowman, W. Paul; Link, Mi 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 2 views

## Background: The pediatric oncology group (pog) conducted a two-arm, randomized study for the treatment of children and adolescents with stage iii small, non-cleaved cell lymphoma (snccl). regimen a, based on the group's previous best treatment for this group of patients, included cyclophosphamid

Feasibility and toxicity of high-dose th

Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: Survey from a single institution

✍ Massimo Magagnoli; Luca Castagna; Monica Balzarotti; Barbara Sarina; Inna Timofe 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views